हाइड्रोकोडोन और क्लोरफेनिरामिन और मिथाइलीन ब्लू का इंटरैक्शन

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.

Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )].

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS See full prescribing information for complete boxed warning.

PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs and Opioids The development of serotonin syndrome has been reported with the use of methylene blue class products.

Serotonergic drugs : Concomitant use may result in serotonin syndrome.

Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Monoamine Oxidase Inhibitors (MAOIs) Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex in patients who are taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days.

MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).

Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone.